Pimodivir
Pimodivir (VX-787) is an orally administered small molecule inhibitor that selectively targets the PB2 subunit of the influenza A virus polymerase complex. It has demonstrated potent antiviral activity in both in vitro assays and in vivo animal models, making it a valuable tool for researching influenza pathogenesis and novel therapeutic strategies.
Product Specifications
CAS Number
1629869-44-8
Product Name Alternative
Inhibit, Influenza A polymerases, Influenza Virus, InfluenzaVirus, Inhibitor, VX-787, Pimodivir, VX 787, VX787
Field of Research
Infectious Disease & Virology
Purity
99.35% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (5.01 mM) ; DMSO:50 mg/mL (125.19 mM)
Smiles
OC (=O) [C@H]1C2CCC (CC2) [C@@H]1Nc1nc (ncc1F) -c1c[nH]c2ncc (F) cc12
Molecular Formula
C20H19F2N5O2
Molecular Weight
399.39
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Girentuximab Biosimilar - Anti-CA9 mAb - Research Grade
SLPI, ID (SLPI, WAP4, WFDC4, Antileukoproteinase, BLPI, HUSI-1, Mucus proteinase inhibitor, Protease inhibitor WAP4, Secretory leukocyte protease inhibitor, Seminal proteinase inhibitor, WAP four-disulfide core domain protein 4) (FITC) discontinued